Tvardi Therapeutics, Inc. TVRD
1.18 USD +0.02 (+2.16%)
At closeNov 13, 2026, 4:00 PM EST
1.17 -0.01 -0.85%
After hours · Nov 13, 4:00 PM ET
1.08 Day range 1.18
0.773 52-week range 5.69
- YTD
- -72.56%
- 1 year
- -71.29%
News
benzinga.com Tvardi Therapeutics Q3 EPS $(0.48) Beats $(0.53) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 18.64 percent increase over losses of…
globenewswire.com Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral,…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8 Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
benzinga.com Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2…
benzinga.com Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of…- benzinga.com Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to
benzinga.com BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5 BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…
benzinga.com Why Is Tvardi Therapeutics Stock Falling Thursday? Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
benzinga.com Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perform to Outperform and announces $10 price target.
benzinga.com Why Is Tvardi Therapeutics Stock Gaining Tuesday? Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen STAT3 inhibitor, TTI-109. Read more.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
benzinga.com BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
benzinga.com Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
benzinga.com Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
benzinga.com This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Analysts think CBRS stock is a buy.
benzinga.com HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9 HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $9.- benzinga.com Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 77.33 percent increase over losses of…
- benzinga.com Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
- benzinga.com Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3 Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
- benzinga.com Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4 Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and lowers the price target from $5 to $4.
- benzinga.com Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3 Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
benzinga.com Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 15.38 percent. This is a 84.21 percent increase over losses…- benzinga.com Tvardi Therapeutics Provides Updates From Phase 2 REVERT IPF Clinical Trial Of TTI-101 In Idiopathic Pulmonary Fibrosis Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo groupTopline healthy volunteer data from…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.92) by 35.8 percent.
- benzinga.com Raymond James Downgrades Tvardi Therapeutics to Market Perform Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform to Market Perform.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.
benzinga.com Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $15 BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to $15.
benzinga.com Dow Surges 1%; Fastenal Shares Fall After Q3 Results - benzinga.com Barclays Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $61 Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $61.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Tvardi Therapeutics Said Preliminary Data From Phase 2 REVERT Trial of TTI-101 In Idiopathic Pulmonary Fibrosis Show That The Study Did Not Meet Its Goals The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was…
- benzinga.com Tvardi Therapeutics Q2 EPS $(1.00) Misses $(0.58) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.58) by 73.01 percent.
- benzinga.com Raymond James Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $62 Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $62.
- benzinga.com Cantor Fitzgerald Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $52 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $52.